Haematologica最新文献_第8页

Use of upfront autologous stem cell transplantation in myeloma patients aged >65 years: a population-based study by the Nordic Myeloma Study Group. 北欧骨髓瘤研究小组开展的一项基于人群的研究：在bb0 ~ 65岁骨髓瘤患者中使用前期自体干细胞移植。

IF 10.1 1区医学

Haematologica Pub Date : 2025-09-04 DOI: 10.3324/haematol.2025.287344

Kari Lenita Falck Moore,Samundur Rognvaldsson,Agoston G Szabo,Vilmantė Vaitekėnaitė,Diana Loigom,Anna Genell,Jonathan Thorsen,Jakob N Norgaard,Sigrun Thorsteinsdottir,Dorota Knut-Bojanowska,Anna Lysen,Fredrik Schjesvold,Valdas Peceliunas,Ain Kaare,Katrin Palk,Maris Parnat,Alexander Sigurdsson,Annette J Vangsted,Cecilie H Blimark

引用次数: 0

What's hidden in plain sight? Impact of clonal hematopoiesis on the risk and progression of non-hematologic cancers. 什么隐藏在显而易见的地方？克隆造血对非血液学癌症风险和进展的影响。

IF 10.1 1区医学

Haematologica Pub Date : 2025-09-04 DOI: 10.3324/haematol.2025.287424

José C Martínez,Catherine C Coombs

{"title":"What's hidden in plain sight? Impact of clonal hematopoiesis on the risk and progression of non-hematologic cancers.","authors":"José C Martínez,Catherine C Coombs","doi":"10.3324/haematol.2025.287424","DOIUrl":"https://doi.org/10.3324/haematol.2025.287424","url":null,"abstract":"Clonal hematopoiesis (CH) is a frequently observed phenomenon in aging individuals without apparent illness and exhibits an increased prevalence in cancer patients. Mechanistic studies indicate that mutant immune cells alter the tumor microenvironment, leading to increased inflammation, blood vessel formation, and immune cell exhaustion. Paradoxically, these changes also preserve stem-like T-cell pools that can be utilized by immunotherapy. CH may be incidentally detected in patients whose solid tumors are profiled by next-generation sequencing. Clinically, CH confers higher risks of therapy-related myeloid neoplasms, cardiovascular and inflammatory toxicities, and context-specific changes in treatment efficacy. Moreover, tumorinfiltrating CH independently shortens survival. Two validated risk scores can inform the risk for myeloid malignancy, yet surveillance, cardiometabolic management, and regimen selection still primarily rely on expert consensus. Because CH may be discovered incidentally, rigorous confirmation of variant origin when CH is suspected is essential to avoid misdirected therapy. We propose a pragmatic approach: confirm CH with paired blood sequencing when feasible; integrate high-risk features into risk stratification, counseling, and monitoring for cytopenias and cardiovascular events; and prefer less genotoxic regimens when the oncologic benefit is comparable. Early trials blocking interleukin-1β suggest that targeting inflammation driven by CH may improve outcomes in patients with solid tumors. Prospective studies informed by mutation analysis and tracking clonal changes and inflammatory markers are needed to determine if routine CH assessment can be integrated into precision oncology to improve outcomes for patients with solid tumors and CH.","PeriodicalId":12964,"journal":{"name":"Haematologica","volume":"19 1","pages":""},"PeriodicalIF":10.1,"publicationDate":"2025-09-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144962627","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Romiplostim for aplastic anemia: beyond an eltrombopag alternative. Romiplostim治疗再生障碍性贫血：超越电子宝的替代品。

IF 10.1 1区医学

Haematologica Pub Date : 2025-09-04 DOI: 10.3324/haematol.2025.288632

Shinji Nakao

引用次数: 0

Impact of letermovir on Cytomegalovirus-specific T-cells reconstitution after allogeneic hematopoietic stem cell transplantation in the post-transplant cyclophosphamide era. letermovir对移植后环磷酰胺时代同种异体造血干细胞移植后巨细胞病毒特异性t细胞重构的影响。

IF 10.1 1区医学

Haematologica Pub Date : 2025-09-04 DOI: 10.3324/haematol.2025.288306

Elena Tassi,Giorgio Orofino,Valeria Beretta,Veronica Valtolina,Gregorio Maria Bergonzi,Maddalena Noviello,Elisabetta Xue,Matteo Doglio,Andrea Acerbis,Lorenzo Lazzari,Fabio Giglio,Simona Piemontese,Elisa Diral,Alessandro Bruno,Francesca Farina,Raffaele Dell'Acqua,Luca Vago,Andrea Assanelli,Annalisa Ruggeri,Daniela Clerici,Consuelo Corti,Maria Teresa Lupo-Stanghellini,Fabio Ciceri,Chiara Bonini,Raffaella Greco

引用次数: 0

SLC25A1 reprograms mitochondrial and fatty acid metabolism to promote the progression of acute myeloid leukemia. SLC25A1重编程线粒体和脂肪酸代谢，促进急性髓性白血病的进展。

IF 10.1 1区医学

Haematologica Pub Date : 2025-09-04 DOI: 10.3324/haematol.2024.287269

Miao Chen,Wenze Li,Yuan Tao,Chenglong Hu,Rui Ge,Sijing Kang,Pengjie Yue,Cheuk Him Man,Lan Wang,Xiaojing Yan

{"title":"SLC25A1 reprograms mitochondrial and fatty acid metabolism to promote the progression of acute myeloid leukemia.","authors":"Miao Chen,Wenze Li,Yuan Tao,Chenglong Hu,Rui Ge,Sijing Kang,Pengjie Yue,Cheuk Him Man,Lan Wang,Xiaojing Yan","doi":"10.3324/haematol.2024.287269","DOIUrl":"https://doi.org/10.3324/haematol.2024.287269","url":null,"abstract":"Abnormal metabolic reprogramming is a hallmark of acute myeloid leukemia (AML), contributing to leukemia initiation, progression and drug resistance. The key mitochondrial citrate transporter SLC25A1 plays an essential role in regulating cellular energy metabolism and shows to play an important role in lipid metabolism regulation. However, the role of SLC25A1 in the pathogenesis and aberrant lipid metabolism in AML remain unexplored. In this study, our analysis of public datasets and patient samples revealed that SLC25A1 expression was markedly elevated in AML and was associated with poor prognosis. Knockdown or pharmacological inhibition of SLC25A1 significantly suppressed AML cell proliferation by inducing apoptosis, without affecting cell cycle progression or differentiation. Moreover, SLC25A1 proved vital for AML tumorigenesis in vivo. Mechanistically, we demonstrated that SLC25A1 inhibition disrupted citrate homeostasis, leading to mitochondrial dysfunction and reduced fatty acid metabolism. Notably, we developed a novel SLC25A1 inhibitor, CTPI3, which effectively inhibits the progression of AML in vivo, and synergizes with venetoclax to kill AML cells by mitochondrial and fatty acid metabolism regulation. In summary, our findings highlight that SLC25A1 plays a vital role of in maintaining AML cell survival and regulating its drug sensitivity, and further developed a more effective novel drug targeting SLC25A1, providing additional therapeutic options for venetoclax-resistant patients and highlighting SLC25A1 as a promising biomarker and therapeutic target for AML.","PeriodicalId":12964,"journal":{"name":"Haematologica","volume":"36 1","pages":""},"PeriodicalIF":10.1,"publicationDate":"2025-09-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144962655","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Peripheral monoclonal plasmacytosis in infective endocarditis: a tangled web. 感染性心内膜炎的外周单克隆浆细胞增多症：一个纠结的网。

IF 10.1 1区医学

Haematologica Pub Date : 2025-09-04 DOI: 10.3324/haematol.2025.288276

Giuseppe Bertuglia,Enrico Amaducci,Davide Stella,Angela Dattolo,Giorgia Andrea Impala,Sabrina Aliberti,Giuseppina Prato,Mauro Giorgi,Benedetto Bruno,Francesca Gay

引用次数: 0

Reporting blast percentage for response assessment in acute leukemias: recommendations from an EHA/ELN expert panel. 报告急性白血病反应评估的爆炸百分比：EHA/ELN专家组的建议。

IF 10.1 1区医学

Haematologica Pub Date : 2025-09-04 DOI: 10.3324/haematol.2025.288228

Sa A Wang,Leonor Arenillas,Francesco Buccisano,Monika Bruggemann,Wolfgang Kern,Manuel Menes,Adriana Plesa,Louisa Stone,Dominique Wellnitz,David A Westerman,Brent L Wood,Sylvie D Freeman

{"title":"Reporting blast percentage for response assessment in acute leukemias: recommendations from an EHA/ELN expert panel.","authors":"Sa A Wang,Leonor Arenillas,Francesco Buccisano,Monika Bruggemann,Wolfgang Kern,Manuel Menes,Adriana Plesa,Louisa Stone,Dominique Wellnitz,David A Westerman,Brent L Wood,Sylvie D Freeman","doi":"10.3324/haematol.2025.288228","DOIUrl":"https://doi.org/10.3324/haematol.2025.288228","url":null,"abstract":"Evaluation of bone marrow blast percentage is paramount to response criteria in acute leukemias. There is an identified need within the framework of updated laboratory practices to reduce inconsistencies in methodologies used by clinical laboratories to report blast values and clarify aspects of reporting. Representatives from international specialised working groups including the European Hematology Association (EHA) Diagnosis in Hematological Diseases Specialised Working Group and the European LeukemiaNet (ELN) produced consensus guidance for harmonised blast assessment to define response categories in acute leukemic patients. These address sampling best practice, key considerations for generating the most accurate blast enumeration and the limitations across the methodologies in acute lymphoblastic leukemia (ALL), acute myeloid leukemia (AML) and acute leukemia of ambiguous lineage. An integrated reporting scheme for deriving blast percentage is provided for ALL and AML. This incorporates results from appropriate measurable residual disease assays with morphological crosscheck. The practical guide and approach presented herein should facilitate uniform reporting standards both within clinical trials and in broader clinical practice.","PeriodicalId":12964,"journal":{"name":"Haematologica","volume":"47 1","pages":""},"PeriodicalIF":10.1,"publicationDate":"2025-09-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144962657","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

CHIP ahoy: charting a decade of discovery in clonal hematopoiesis. CHIP：描绘克隆造血十年的发现。

IF 10.1 1区医学

Haematologica Pub Date : 2025-09-04 DOI: 10.3324/haematol.2023.283896

Casey K Wong,Alexandra McDonald,Marco M Buttigieg,Michael J Rauh

{"title":"CHIP ahoy: charting a decade of discovery in clonal hematopoiesis.","authors":"Casey K Wong,Alexandra McDonald,Marco M Buttigieg,Michael J Rauh","doi":"10.3324/haematol.2023.283896","DOIUrl":"https://doi.org/10.3324/haematol.2023.283896","url":null,"abstract":"Clonal hematopoiesis (CH) involves the expansion of hematopoietic stem cells with ageacquired mutations linked to myeloid malignancy. Advances in next-generation and single-cell sequencing, along with computational modeling, have expanded our ability to detect both common and rare CH drivers, including single-nucleotide variants and mosaic chromosomal alterations, with increasing sensitivity. While sequencing methods differ in accuracy, cost, and ability to detect low-frequency variants, they have deepened our understanding of CH biology. A growing body of evidence has identified both somatic drivers, such as variants in DNMT3A, TET2, and ASXL1, and germline genetic variants that modify CH risk, highlighting the complex interplay between inherited and acquired factors. These collective discoveries are guiding the development of targeted therapies and interventions, particularly for individuals at risk of progression to myeloid neoplasms or cardiovascular disease. Additionally, CH is emerging as a clinically relevant factor in the treatment of solid tumors, where it may influence the tumour microenvironment, treatment response and the risk of therapy-related complications. Risk stratification models are facilitating earlier identification and monitoring of high-risk individuals, enabling personalized treatment decisions. The scope of CH management continues to expand, from surveillance to intervention, with ongoing trials testing preventive strategies in high-risk populations. Emerging trial frameworks emphasize risk stratification, age-appropriateness, inclusive recruitment, decentralized trial models, and the use of traditional clinical and novel endpoints. Together, these advances reflect a shift from passive observation to proactive intervention, charting a course for early detection, precision treatment, and prevention in CH care.","PeriodicalId":12964,"journal":{"name":"Haematologica","volume":"36 1","pages":""},"PeriodicalIF":10.1,"publicationDate":"2025-09-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144962658","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

A founder heterozygous mutation in Methyl-CpG binding domain protein 4 (MBD4) prevalent among Israeli Christian Arabs predisposes to increased mutagenesis. 甲基- cpg结合域蛋白4 （MBD4）的创始杂合突变在以色列基督教阿拉伯人中普遍存在，易于增加突变。

IF 10.1 1区医学

Haematologica Pub Date : 2025-09-04 DOI: 10.3324/haematol.2025.287690

Gal Dadi,Sara Rosen,Hadas Naor,Elias Hellou,Noa Chapal-Ilani,Tal Bacharach,Nathali Kaushansky,Liran L Shlush

引用次数: 0

Infection risk in 158 patients with relapsed/refractory multiple myeloma treated with bispecific antibodies: a single-center experience. 158例接受双特异性抗体治疗的复发/难治性多发性骨髓瘤患者的感染风险：单中心研究

IF 10.1 1区医学

Haematologica Pub Date : 2025-09-04 DOI: 10.3324/haematol.2025.288187

Lorenzo Cani,Sara A Scott,Danielle Roberts,Nisha S Joseph,Craig C Hofmeister,Vikas A Gupta,Madhav V Dhodapkar,Sagar Lonial,Ajay K Nooka,Jonathan L Kaufman

{"title":"Infection risk in 158 patients with relapsed/refractory multiple myeloma treated with bispecific antibodies: a single-center experience.","authors":"Lorenzo Cani,Sara A Scott,Danielle Roberts,Nisha S Joseph,Craig C Hofmeister,Vikas A Gupta,Madhav V Dhodapkar,Sagar Lonial,Ajay K Nooka,Jonathan L Kaufman","doi":"10.3324/haematol.2025.288187","DOIUrl":"https://doi.org/10.3324/haematol.2025.288187","url":null,"abstract":"Four bispecific antibodies (BsAbs) are approved for the treatment of relapsed refractory multiple myeloma (RRMM), but their use is associated with infection risks, requiring mitigation strategies. This single-center retrospective study evaluated the incidence, etiology, and risk factors for infections in 158 RRMM patients treated with BsAbs. A total of 101 patients received BCMAxCD3 BsAbs (teclistamab and elranatamab), and 57 GPRC5DxCD3 BsAb (talquetamab). Prophylactic measures included herpes zoster and Pneumocystis jirovecii coverage, along with monthly intravenous immunoglobulin (IVIG) as primary prophylaxis. Tocilizumab was used for the prevention of cytokine release syndrome and immune effector cell-associated neurotoxicity syndrome, and BsAb frequency was reduced in responding patients. Cytomegalovirus (CMV) viral load was assessed monthly. Median follow-up was 6.1 vs. 4.5 months for anti-BCMA vs. anti-GPRC5D group. The cumulative incidence of the first any-grade infection at 5 and 10 months was 38.6% and 47.9% in the anti-BCMA group, and 28.1% and 30.3% in the anti-GPRC5D group (p=0.06). IVIG administration significantly reduced the risk of grade ≥3 infections in multivariate analysis (HR 0.38, p.","PeriodicalId":12964,"journal":{"name":"Haematologica","volume":"32 1","pages":""},"PeriodicalIF":10.1,"publicationDate":"2025-09-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144962654","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0